This is not a one-time failure. This is a pattern. And the federal government's answer to it is to ask the industry — nicely — to do better.
In the past year, two separate U.S. brands of powdered infant formula have been linked to botulism outbreaks. A contaminated ingredient triggered nearly 150 suspected poisoning cases across ten countries. Babies — some just weeks old — have been hospitalized from products their parents bought at major retail chains, trusting that someone in power had made sure those products were safe to feed a newborn.
On July 13, 2026, the Food and Drug Administration responded.
They sent a letter.
The Scale of What Has Happened
Let's be precise about what we're dealing with, because this is not a single isolated recall.
Outbreak One — ByHeart: The first confirmed U.S. botulism outbreak linked to infant formula in nearly 50 years. Forty-eight babies sickened across 17 states. The outbreak ran through early 2026 before being contained.
Outbreak Two — Nara Organics: Four infants, including a Pennsylvania baby, hospitalized with botulism type A. The outbreak began in April 2026 and, as of this writing, is still ongoing.
The Global Contamination Event: Separate from the botulism outbreaks, contaminated arachidonic acid (ARA) oil — a common ingredient added to infant formula — produced nearly 150 suspected and confirmed cases of cereulide intoxication across ten countries. In May 2026, a2 Milk recalled formula batches after detecting the toxin. This was a supply chain contamination that crossed manufacturers, brands, and borders.
Three crises. Two of them still unresolved. All of them involving the same category of product: infant formula fed to the most vulnerable humans on earth.
What the FDA Did
The FDA sent a letter to infant formula manufacturers urging them to exercise "substantive oversight" of their suppliers. The agency said it "expects" manufacturers to understand where their ingredients come from, how they're produced, what risks they carry, and whether those risks are being controlled.
It recommended that companies monitor safety signals — recall notifications, outbreak investigations, import alerts.
That's it. No mandatory testing requirements. No new regulations. No enforcement action. No prohibition on the use of unverified ingredients in infant formula. A letter asking an industry to please pay more attention.
What the FDA Could Have Done — And Didn't
This is not a situation where the FDA lacks the power to act. It is a situation where the FDA chose not to use the power it has.
Under the federal Infant Formula Act and its own regulations — 21 CFR Parts 106 and 107 — the FDA has authority to set and enforce manufacturing practices, quality control standards, and testing requirements for every infant formula sold in the United States. The agency can require that manufacturers verify ingredient safety before those ingredients ever touch formula. It can mandate specific pathogen testing before a product is released to market. It can prohibit the use of ingredient sources that haven't been audited and certified safe.
Congress has already signaled what mandatory action looks like: the Infant Formula Safety Modernization Act of 2026 was introduced to direct the FDA to enforce standardized pathogen and microorganism testing of formula products and manufacturing facilities. The FDA didn't need Congress to introduce that bill to act — it has the regulatory authority to impose those requirements through rulemaking right now, without waiting for legislation.
States have shown it can be done. Connecticut, Illinois, and Vermont have enacted laws requiring monthly testing, public disclosure of results, and enhanced labeling. States — with a fraction of the FDA's resources and authority — are doing what the federal regulator won't.
Instead, the FDA sent a letter.
Why This Matters — And Who Pays the Price
There is a cynical logic to regulatory inaction. Rulemaking is slow, politically contentious, and opposed by well-funded industries. Sending a letter is fast, frictionless, and generates a press release. The industry gets to say it received guidance. The agency gets to say it responded. And the cost of the next outbreak — the hospitalized infants, the traumatized families, the long-term developmental monitoring — falls entirely on the families it happened to.
This is not an abstraction. When a product made by a company that answers to shareholders poisons a baby, and the federal agency charged with preventing that outcome chose to write a strongly-worded letter rather than mandate the testing that would have caught it — those families have nowhere to turn except the civil courts.
The Civil Justice System Is the Only Real Accountability
People sometimes ask why we need product liability lawsuits when we have regulators. The infant formula crisis is the answer.
When the FDA issues a letter, there is no consequence for ignoring it. When a jury returns a verdict — or a company faces the prospect of one — there are consequences. Compensatory damages for medical costs, pain, suffering, and long-term harm. Potentially punitive damages where a company's conduct was reckless. Public disclosure through litigation of internal documents, testing records, and supply chain decisions that regulators never forced into the open.
Product liability litigation does not just compensate individual families. It changes industry behavior in a way that voluntary guidance cannot. Companies invest in quality control when the alternative is a trial. They audit their suppliers when a contaminated ingredient means a lawsuit. They test their products before release when failure to test becomes evidence of negligence.
The FDA's letter asks manufacturers to do these things voluntarily. The civil justice system requires them to do these things — or face the financial and reputational cost of not having done so.
If your infant consumed Nara Organics formula, ByHeart formula, or any recalled product and became ill, a letter from the government to the manufacturer is not justice. It is not accountability. And it will not change what happened to your child.
A lawsuit might.
If your baby was hospitalized, showed symptoms of botulism, or consumed any recalled infant formula, contact me immediately. These cases require prompt action to preserve evidence before it disappears. Consultations are always free — no fee unless I win.